• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4619599)   Today's Articles (5837)   Subscriber (49403)
For: Williams TA, Blyth CP. Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. Eye (Lond) 2011;25:1617-21. [PMID: 21921947 DOI: 10.1038/eye.2011.224] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]  Open
Number Cited by Other Article(s)
1
Kuboi T, Chuck RS, Pineda R, Bhushan R, Goswamy A, Olson RJ. Subgroup Analysis from a Phase 1/2 Randomized Clinical Trial of 2.6% EDTA Ophthalmic Solution in Patients with Age-Related Cataract. Am J Ophthalmol 2024:S0002-9394(24)00349-0. [PMID: 39098755 DOI: 10.1016/j.ajo.2024.07.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2024] [Revised: 07/25/2024] [Accepted: 07/26/2024] [Indexed: 08/06/2024]
2
Song YY, Seong HJ, Kim JT, Lee SC, Lee MW. Features of optical coherence tomography angiography in age-related macular degeneration with residual fluid after three loading doses of aflibercept. EYE AND VISION (LONDON, ENGLAND) 2024;11:4. [PMID: 38297400 PMCID: PMC10832073 DOI: 10.1186/s40662-023-00372-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 08/13/2023] [Accepted: 12/25/2023] [Indexed: 02/02/2024]
3
Lowater SJ, Grauslund J, Subhi Y, Vergmann AS. Clinical Trials and Future Outlooks of the Port Delivery System with Ranibizumab: A Narrative Review. Ophthalmol Ther 2024;13:51-69. [PMID: 38055121 PMCID: PMC10776525 DOI: 10.1007/s40123-023-00843-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Accepted: 10/20/2023] [Indexed: 12/07/2023]  Open
4
Calcagni A, Howells O, Bartlett H, Denniston AKO, Gibson JM, Hogg CR, Matthews TD, Eperjesi F. Comparison of colour contrast sensitivity in eyes at high risk of neovascular age-related macular degeneration with and without subsequent choroidal neovascular membrane development. Eye (Lond) 2023;37:297-302. [PMID: 35058600 PMCID: PMC9873808 DOI: 10.1038/s41433-021-01875-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 10/27/2021] [Accepted: 11/24/2021] [Indexed: 01/28/2023]  Open
5
CHARACTERISTICS OF AGE-RELATED MACULAR DEGENERATION SHOWING A POOR RESPONSE TO THREE LOADING DOSES OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR. Retina 2023;43:8-15. [PMID: 36161992 DOI: 10.1097/iae.0000000000003628] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Accepted: 09/17/2022] [Indexed: 12/24/2022]
6
White J, Hambisa MT, Cavenagh D, Dolja-Gore X, Byles J. Understanding the relationship between eye disease and driving in very old Australian women: a longitudinal thematic evaluation. BMC Ophthalmol 2022;22:277. [PMID: 35751055 PMCID: PMC9233390 DOI: 10.1186/s12886-022-02506-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Accepted: 05/05/2022] [Indexed: 11/30/2022]  Open
7
Lotery A, Clemens A, Tuli R, Xu X, Shimura M, Nardi M, Ziemssen F, Dunger-Baldauf C, Tadayoni R. Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study. Eye (Lond) 2021;36:1656-1661. [PMID: 34326500 PMCID: PMC9307792 DOI: 10.1038/s41433-021-01702-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 07/13/2021] [Accepted: 07/15/2021] [Indexed: 11/24/2022]  Open
8
RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study. Retina 2021;40:1673-1685. [PMID: 31764612 PMCID: PMC7447127 DOI: 10.1097/iae.0000000000002670] [Citation(s) in RCA: 66] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
9
REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY: Twelve-Month Results From the LUMINOUS Study. Retina 2021;40:1529-1539. [PMID: 31385918 PMCID: PMC7392585 DOI: 10.1097/iae.0000000000002624] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
10
Beka S, Strauss RW, Podkowinski D, Mursch-Edlmayr AS, Mariacher S, Hofer AS, Bolz M. Efficacy of a disease management program of a tertiary center and ophthalmologic practitioners for the treatment of neovascular age related macular degeneration. Ophthalmologica 2021;245:10-18. [PMID: 34023820 DOI: 10.1159/000517188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Accepted: 05/05/2021] [Indexed: 11/19/2022]
11
Meira J, Carneiro J, Madeira C, Falcão M, Beato J, Correia S, Falcão-Reis F, Carneiro Â. Effectiveness of treat-and-extend versus pro re nata regimens in the treatment of Neovascular Age Macular Degeneration: A Real World Comparison. ARCHIVOS DE LA SOCIEDAD ESPANOLA DE OFTALMOLOGIA 2020;95:263-270. [PMID: 32370878 DOI: 10.1016/j.oftal.2020.03.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Revised: 03/01/2020] [Accepted: 03/05/2020] [Indexed: 06/11/2023]
12
Carrasco J, Pietsch GA, Nicolas MP, Koerber C, Bennison C, Yoon J. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies. Adv Ther 2020;37:300-315. [PMID: 31728825 PMCID: PMC6979459 DOI: 10.1007/s12325-019-01147-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Indexed: 12/22/2022]
13
Khanani AM, Skelly A, Bezlyak V, Griner R, Torres LR, Sagkriotis A. SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States. Ophthalmol Retina 2019;4:122-133. [PMID: 31812631 DOI: 10.1016/j.oret.2019.09.009] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Revised: 09/13/2019] [Accepted: 09/17/2019] [Indexed: 01/10/2023]
14
Wei W, Weisberger A, Zhu L, Cheng Y, Liu C. Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study. Ophthalmol Retina 2019;4:57-66. [PMID: 31902472 DOI: 10.1016/j.oret.2019.08.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Revised: 07/26/2019] [Accepted: 08/03/2019] [Indexed: 01/22/2023]
15
Nishikawa K, Oishi A, Hata M, Miyake M, Ooto S, Yamashiro K, Miyata M, Tamura H, Ueda-Arakawa N, Takahashi A, Kawashima Y, Tsujikawa A. Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy. Sci Rep 2019;9:3620. [PMID: 30842468 PMCID: PMC6403223 DOI: 10.1038/s41598-019-39995-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2018] [Accepted: 02/07/2019] [Indexed: 12/26/2022]  Open
16
Lowry EA, Nguyen V, Daien V, Barthelmes D, Gillies MC. Outcomes in Neovascular Age-Related Macular Degeneration when Neovascular Lesion Activity Is Uncertain: Observational Study. Ophthalmol Retina 2018;2:531-538. [PMID: 31047605 DOI: 10.1016/j.oret.2017.10.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Revised: 09/29/2017] [Accepted: 10/02/2017] [Indexed: 06/09/2023]
17
Mori R, Tanaka K, Yuzawa M. Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity. Medicine (Baltimore) 2018;97:e11188. [PMID: 29924037 PMCID: PMC6024465 DOI: 10.1097/md.0000000000011188] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]  Open
18
Al-Khersan H, Hariprasad SM, Chhablani J. Reply. Am J Ophthalmol 2018;186:165. [PMID: 29233534 DOI: 10.1016/j.ajo.2017.10.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2017] [Accepted: 10/30/2017] [Indexed: 11/17/2022]
19
Qi HJ, Li XX, Zhang JY, Zhao MW. Efficacy and safety of ranibizumab for wet age-related macular degeneration in Chinese patients. Int J Ophthalmol 2017;10:91-97. [PMID: 28149783 PMCID: PMC5225355 DOI: 10.18240/ijo.2017.01.15] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Accepted: 08/25/2016] [Indexed: 11/23/2022]  Open
20
Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I, Priglinger S, Wenzel A, Barnes E, Gekkieva M, Pilz S, Monés J. Individualized Stabilization Criteria–Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion. Ophthalmology 2016;123:1332-44. [PMID: 27039022 DOI: 10.1016/j.ophtha.2016.02.030] [Citation(s) in RCA: 71] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Revised: 02/16/2016] [Accepted: 02/17/2016] [Indexed: 12/23/2022]  Open
21
TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN. Retina 2016;36:875-80. [DOI: 10.1097/iae.0000000000000814] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
22
Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion. Ophthalmology 2016;123:1101-11. [DOI: 10.1016/j.ophtha.2016.01.011] [Citation(s) in RCA: 69] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Revised: 01/07/2016] [Accepted: 01/09/2016] [Indexed: 11/15/2022]  Open
23
Razi F, Haq A, Tonne P, Logendran M. Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes. Clin Ophthalmol 2016;10:313-9. [PMID: 26937168 PMCID: PMC4762441 DOI: 10.2147/opth.s97775] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]  Open
24
Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond) 2015;30:270-86. [PMID: 26634711 DOI: 10.1038/eye.2015.217] [Citation(s) in RCA: 92] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2015] [Accepted: 09/21/2015] [Indexed: 12/28/2022]  Open
25
Williams GS, Seow E, Evans H, Owoniyi M, Evans S, Blyth C. Factors affecting visual acuity after one year of follow up after repeated intravitreal ranibizumab for macular degeneration. Saudi J Ophthalmol 2015;29:187-91. [PMID: 26155076 PMCID: PMC4487938 DOI: 10.1016/j.sjopt.2015.02.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Revised: 01/26/2015] [Accepted: 02/25/2015] [Indexed: 11/05/2022]  Open
26
Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, Harding S, Johnston RL, Kelly SP, Kelly S, Lotery A, Mahmood S, Menon G, Sivaprasad S, Talks J, Tufail A, Yang Y. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond) 2015;29:721-31. [PMID: 25882328 DOI: 10.1038/eye.2015.48] [Citation(s) in RCA: 182] [Impact Index Per Article: 20.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2014] [Accepted: 03/01/2015] [Indexed: 11/09/2022]  Open
27
Barikian A, Mahfoud Z, Abdulaal M, Safar A, Bashshur ZF. Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration. Am J Ophthalmol 2015;159:131-7. [PMID: 25308787 DOI: 10.1016/j.ajo.2014.10.005] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2014] [Revised: 09/30/2014] [Accepted: 10/04/2014] [Indexed: 12/31/2022]
28
Kato A, Yasukawa T, Suga K, Hirano Y, Nozaki M, Yoshida M, Ogura Y. Intravitreal ranibizumab for patients with neovascular age-related macular degeneration with good baseline visual acuity. Ophthalmologica 2014;233:27-34. [PMID: 25412682 DOI: 10.1159/000368249] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2014] [Accepted: 09/09/2014] [Indexed: 11/19/2022]
29
Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T, McKibbin M, Downey L, Natha S, Chakravarthy U, Bailey C, Khan R, Antcliff R, Armstrong S, Varma A, Kumar V, Tsaloumas M, Mandal K, Bunce C, Tufail A. The Neovascular Age-Related Macular Degeneration Database. Ophthalmology 2014;121:1966-75. [DOI: 10.1016/j.ophtha.2014.04.026] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2013] [Revised: 12/04/2013] [Accepted: 04/22/2014] [Indexed: 10/25/2022]  Open
30
Nomura Y, Takahashi H, Tan X, Fujimura S, Obata R, Yanagi Y. Effects of vitreomacular adhesion on ranibizumab treatment in Japanese patients with age-related macular degeneration. Jpn J Ophthalmol 2014;58:443-7. [DOI: 10.1007/s10384-014-0333-5] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2014] [Accepted: 06/03/2014] [Indexed: 01/30/2023]
31
COMPARISON OF INTRAVITREAL RANIBIZUMAB IN PHAKIC AND PSEUDOPHAKIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH GOOD BASELINE VISUAL ACUITY. Retina 2014;34:853-9. [DOI: 10.1097/iae.0000000000000024] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
32
The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 2014;121:1092-101. [PMID: 24461586 DOI: 10.1016/j.ophtha.2013.11.031] [Citation(s) in RCA: 233] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2013] [Revised: 11/18/2013] [Accepted: 11/18/2013] [Indexed: 10/25/2022]  Open
33
Ozkaya A, Alkin Z, Osmanbasoglu O, Ozkaya H, Demirok A. Intravitreal ranibizumab for neovascular age-related macular degeneration patients with good baseline visual acuity and the predictive factors for visual outcomes. J Fr Ophtalmol 2014;37:280-7. [DOI: 10.1016/j.jfo.2013.08.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2013] [Revised: 07/22/2013] [Accepted: 08/26/2013] [Indexed: 11/28/2022]
34
Erol MK, Ozdemir O, Coban DT, Ceran BB, Bulut M. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity. Semin Ophthalmol 2014;29:108-13. [PMID: 24409939 DOI: 10.3109/08820538.2013.839716] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
35
INTRAVITREAL BEVACIZUMAB IN THE MANAGEMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina 2013;33:1828-35. [DOI: 10.1097/iae.0b013e3182877a0d] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
36
Menon G, Chandran M, Sivaprasad S, Chavan R, Narendran N, Yang Y. Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial). Eye (Lond) 2013;27:959-63. [PMID: 23743535 PMCID: PMC3740324 DOI: 10.1038/eye.2013.93] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2013] [Accepted: 04/14/2013] [Indexed: 01/14/2023]  Open
37
Manna A, Oyede O, Ning B, Yang Y, Narendran N. Avastin and Lucentis: what do patients know? A prospective questionnaire survey. JRSM SHORT REPORTS 2013;4:2042533313484146. [PMID: 24040500 PMCID: PMC3767069 DOI: 10.1177/2042533313484146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
38
Muniraju R, Ramu J, Sivaprasad S. Three-year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Ophthalmologica 2013;230:27-33. [PMID: 23635665 DOI: 10.1159/000350238] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2013] [Accepted: 02/25/2013] [Indexed: 11/19/2022]
39
Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab. J Ophthalmol 2013;2013:268438. [PMID: 23533703 PMCID: PMC3595676 DOI: 10.1155/2013/268438] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2012] [Accepted: 01/23/2013] [Indexed: 11/30/2022]  Open
40
Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity. Retina 2013;32:1811-20. [PMID: 22825407 DOI: 10.1097/iae.0b013e31825db771] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
41
Gruber N, Mosimann UP, Müri RM, Nef T. Vision and night driving abilities of elderly drivers. TRAFFIC INJURY PREVENTION 2013;14:477-485. [PMID: 23683029 DOI: 10.1080/15389588.2012.727510] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
42
Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab? Eye (Lond) 2012;27:56-64. [PMID: 23174752 DOI: 10.1038/eye.2012.225] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA